Richard Kozakiewicz, MD in Chester, MT - Family Medicine

Richard Kozakiewicz, MD is a Family Medicine physician based in Chester, Montana. Richard Kozakiewicz is licensed to practice in Montana (license number 7888) and his current practice location is 418 W Monroe Ave, Chester, Montana. He can be reached at his office (for appointments etc.) via phone at (406) 759-5194.

NPI number for Richard Kozakiewicz is 1417046350 and his current mailing address is Po Box 506, Chester, Montana. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1417046350.

Contact Information

	Richard Kozakiewicz, MD
	418 W Monroe Ave, Chester, MT 59522-0506
	(406) 759-5194
	Not Available

Physician's Profile

Full Name	Richard Kozakiewicz
Gender	Male
Speciality	Family Medicine
Location	418 W Monroe Ave, Chester, Montana
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1417046350
Provider Enumeration Date: 10/11/2006
Last Update Date: 07/09/2007

Medical Identifiers

Medical identifiers for Richard Kozakiewicz such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1417046350	NPI	-	NPPES
0068612	Medicaid	MT
0720273	Medicaid	MT

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	7888 (Montana)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Richard Kozakiewicz is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Richard Kozakiewicz, MD Po Box 506, Chester, MT 59522-0506 Ph: (406) 759-5194	Richard Kozakiewicz, MD 418 W Monroe Ave, Chester, MT 59522-0506 Ph: (406) 759-5194

News Archive

Study may pave way for potential drug targets in lung cancer treatment

Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy.

Recipients of comprehensive primary care twice as likely to rate healthcare as high-quality

Chronically ill older adults who are closely supported by a nurse-physician primary care team are twice as likely to rate their health care as high-quality than those who receive usual care, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health.

Summer camp pairs 'smores and anti-abortion activism

State news on abortion focuses on a summer camp that trains anti-abortion activists and a Kansas City Planned Parenthood whose charges of performing illegal late-term abortions were dismissed in order to narrow a case against it.

FDA revises guidance on changes to an approved NDA, ANDA

FDA has issued a revised guidance to help drugmakers determine how they should report postapproval manufacturing changes to new drug applications (NDAs) or abbreviated new drug applications (ANDAs).

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

Richard Kozakiewicz, MD - Family Medicine in Chester, MT